

**Anti-Propertin (human)  
Mouse monoclonal antibody**

Subclass: IgG<sub>1</sub>/k

PRODUCT NO.

**HYB 039-04**

Clone: 10C5

PRESENTATION

Preparation: Protein-A/G purified

Content: Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: 4-8°C without exposure to light. No precautions necessary during handling.

ANTIGEN

Propertin in plasma is a mixture of cyclic dimers, trimers and tetramers. The molecular weight of the glycosylated monomer is 53 kDa (3). Propertin is a regulator protein of the alternative complement pathway. It stabilizes the C3 convertase exerting its effect by binding to C3b in the C3bBb complex and thereby inhibiting cleavage of C3b by factor I and increasing the affinity for factor B. Serum concentration is approximately 25 µg/mL (2,3).

IMMUNOGEN

Propertin isolated from human plasma adsorbed onto aluminum hydroxide gel (1)

SPECIFICITY

HYB 039-04 is specific for human propertin

EPI TOPE SPECIFICITY

Epitope specificity differs from that of HYB 039-06 but slightly overlap as determined by inhibition ELISA.

REACTIVITY

HYB 039-04 reacts strongly with propertin isolated from human plasma when tested in sandwich ELISA using HYB 039-04 as capture and biotinylated detection antibody, only very low reaction is seen with plasma from patients deficient in propertin. HYB 039-04 works equally well in ELISA with purified propertin coated directly onto the microtiter well. In Western blotting after SDS-PAGE HYB 039-04 reacts with propertin in both reduced (subunits of 25 kDa and 56 kDa) as well as unreduced forms (220 kDa).

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

X63-Ag8.653

IMMUNIZATION

Female CF1 x BALB/c mice immunized by intraperitoneal injection

APPLICATION

Method	Usability	References
ELISA	Yes	
Immunoblotting	Yes	
Immunohistochemistry	Not determined	

REFERENCES

1. Gotze O, Medicus RG, Muller-Eberhard HJ (1977) Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active propertin. J Immunol 118:525-532.
2. Nielsen HE, Koch C (1987) Congenital propertin deficiency and meningococcal infection. Clin Immunol Immunopathol 44:134-139.
3. Fijen CA, Bogaard R, Schipper M, Mannens M, Schlesinger M, Nordin FG, Dankert J, Daha MR, Sjöholm AG, Truedsson L, Kuijper EJ (1999) Propertin deficiency: molecular basis and disease association. Mol Immunol 36:863-867.
4. Bathum L, Hansen H, Teisner B, Koch C, Garred P, Rasmussen K, Wang P (2005) Association between combined propertin and mannose-binding lectin deficiency and infection with *Neisseria meningitidis*. Mol Immunol 43:473-479

**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.